ImmunovantÂ Inc (IMVT) Financials

$38.75

$-0.82 (-2.07%)

As on 09-Sep-2026 16:08EDT

Market cap

$8,107 Mln

Revenue (TTM)

$7 Mln

P/E Ratio

--

P/B Ratio

11

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Operating Revenue	7.10	--	--	--	--	--
Cost of Revenue	0.21	0.41	0.38	0.23	1.32	1.23
Gross Profit	6.89	-0.41	-0.38	-0.23	-1.32	-1.23
Operating Expenses	566.00	532.90	438.15	270.21	208.28	156.03
Operating Profit (EBIT)	-558.91	-532.90	-438.15	-270.21	-208.28	-156.03
Other Income	--	--	--	--	-0.25	-0.78
Profit before Tax	-538.92	-505.39	-412.95	-258.77	-210.95	-156.81
Provision for Tax	-0.70	0.22	0.89	0.57	0.01	-0.08
Profit after Tax (Net Income)	-538.22	-505.61	-413.84	-259.34	-210.96	-156.73
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-210.96	-156.73

Liabilities ($ Mln)	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Shareholder's Funds	735.39	852.59	707.45	617.76	362.49	469.83
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	0.55	1.10	0.35	0.05	1.22
Current Liabilities	117.10	104.42	68.78	48.61	43.30	44.52
Total Liabilities	969.59	957.57	776.22	666.71	405.84	515.56

Assets ($ Mln)	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Non-Current Assets	1.31	8.75	8.56	0.94	1.51	2.63
Current Assets	851.18	948.82	767.66	665.77	404.33	512.93
Total Assets	969.59	957.57	776.22	666.71	405.84	515.56
Total Debt*	--	0.07	0.10	0.14	1.22	2.36
Net Current Assets	734.08	844.40	698.89	617.16	361.04	468.41

Cashflow ($ Mln)	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Cash From Operating Activities	--	-407.31	-375.87	-214.23	-188.19	-106.11
Cash Flow from Investing Activities	--	-0.01	-0.76	-0.36	-0.20	-0.25
Cash from Financing Activities	--	595.76	454.49	472.43	70.89	200.13
Net Cash Inflow / Outflow	--	--	--	--	-117.51	93.76

Financials Ratios	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Adjusted EPS ($)	-2.81	-2.48	-2.73	-1.78	-1.63	-1.35
Cash EPS ($)	--	-2.48	-2.73	-1.78	-1.63	-1.35
Adjusted Book Value ($)	--	4.19	4.67	4.25	2.80	4.04
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.00	-2.48	-1.47	-1.45	-0.91
Free Cash Flow per Share ($)	--	-2.00	-2.48	-1.48	-1.45	-0.91

Profitability Ratios	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
ROCE (%)	--	-64.81	-62.45	-52.84	-50.47	-36.15
ROE (%)	-62.53	-64.82	-62.46	-52.91	-50.69	-36.39
ROA (%)	-63.92	-58.32	-57.36	-48.36	-45.79	-33.78
EBIT Margin (%)	-7,595.70	--	--	--	--	--
Net Margin (%)	-7,585.86	--	--	--	83,383.40	20,067.86
Cash Profit Margin (%)	-0.02	--	--	--	--	--

Growth Ratios	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Revenue Growth (%)	4,334.38	--	--	--	--	--
EBIT Growth (%)	-20.95	-22.39	-59.58	-30.38	-26.56	-45.04
Net Profit Growth (%)	-20.32	-22.17	-59.58	-22.93	-34.60	-45.89
EPS Growth (%)	3.44	0.09	-0.53	-0.10	-0.21	-0.23
Book Value Growth (%)	0.46	--	--	--	--	--

Valuation Ratios	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Price / Earnings	--	-10.01	-6.26	-18.11	-9.53	-4.09
Price / Book Value	10.99	5.94	3.66	7.60	5.55	1.36
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-14.12	-8.23	-4.55	-15.71	-8.25	-0.95
Close Price ($)	38.53	24.84	17.09	32.31	15.51	5.51
High Price ($)	39.28	29.25	34.47	45.58	20.24	17.20
Low Price ($)	14.32	12.72	16.72	14.05	3.15	4.98
Market Cap ($ Cr)	8,107.19	--	--	--	--	--

Solvency Ratios	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Debt to Equity	--	0.00	0.00	0.00	0.00	0.01
Short term debt to equity ratio	--	0.00	0.00	0.00	0.00	0.00
Current Ratio	7.27	9.09	11.16	13.70	9.34	11.52
Quick Ratio	7.27	--	--	14.21	9.34	11.52
Interest Coverage	--	--	--	-5.19	-15.90	-239.41

Operating Efficiency Ratios	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Debtors to sales (%)	9.82	--	--	--	--	--
Asset Turnover	0.01	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	-24,125.88	-19,687.13	--	--
Payable days	--	11,250.86	12,018.86	6,726.29	2,756.20	3,121.97
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.